Following a limited submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2015. Refer to TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | tocilizumab (RoActemra®) | ||
| Formulation | 20 mg/ml concentrate for solution for infusion | ||
| Reference number | 1851 | ||
| Indication | In combination with methotrexate (MTX) for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Musculoskeletal & joint diseases | ||
| Assessment type | Limited | ||
| Status | Superseded | ||
| Advice number | 0514 | ||
| NMG meeting date | 22/01/2014 | ||
| AWMSG meeting date | 19/02/2014 | ||
| Ratification by Welsh Government | 07/05/2014 | ||
| Date of issue | 08/05/2014 | ||
| Date of last review | 17/02/2017 | ||
| NICE guidance | TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
||
| Further information The recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication. |
|||